Fuzzy-Based Application Model and Profile Matching for Recommendation Suitability of Type 2 Diabetic

Agus Wantoro, Admi Syarif, Kurnia Muludi, Khairun Nisa Berawi


Diabetes Mellitus (DM) is a metabolic disease characterized by hyperglycemia due to insulin secretion abnormalities and a global health threat. DM has several types, namely type 1, 2, gestational, and other types. Type 2 diabetes patients have the largest number in the world. DM therapy can be done in 2 (two) ways: improving lifestyle and administering drugs. The problems and risks in recommending drugs are essential in the patient's healing process because they are likely to take medicine for life. Approximately 260,000 patients with type 2 diabetes experienced medication errors in 2017. The doctor's mistake in recommending drugs causes a long healing process and costs more. Recommending drugs requires pharmacological knowledge, and not all hospitals have pharmacologists. Several researchers have researched recommendations for antidiabetic drugs, but no studies have yet been found that discuss recommendations for combination antidiabetic drugs for type two to determine dosage and frequency. The number of medications used is 6 to 7, with many parameters 5 to 8. The latest endocrinology guidelines for 2020 state that in recommending antidiabetic drugs, not only 6 to 7 participants, but still need to maintain other aspects. Therefore, this study aims to build an expert system model with a new approach in recommending antidiabetic drugs with more complete parameters and recommend dosage and frequency. The model developed uses the Fuzzy Profile Matching method. Fuzzy is used to calculate the suitability between the patient's condition and the type of antidiabetic drug. Profile Matching is used to calculate the core factor and secondary factor to obtain each drug's total value. The dose was calculated using the FIS Tsukamoto for inputting low dosage, and high dosage calculated the weighted average value. Determination of frequency using the IF-Then function. Model evaluation is done by comparing recommendation data from doctors. The results of the evaluation of the model obtained an accuracy of 90%. This system will reduce medical personnel errors in recommending antidiabetic drugs that can positively impact patients' time, the healing process, and costs. This study provides knowledge that antidiabetes drugs' determination requires many parameters, while other studies used only 4 to 8. This study also provides an overview of the dosages of drugs that drug companies can produce. Usually, the company only makes low and high dosage. This study shows that creating multiple drug dosage is more efficient for patients.


Model evaluation; diabetic type 2; fuzzy Tsukamoto; profile matching; drugs; dosage; frequency.

Full Text:



WHO, “Global Report on Diabetes,†France, 2016.

ADA, “Classi fi cation and Diagnosis of Diabetes: Standards of Medical Care in Diabetes d 2020,†Care.diabetesjournals.org, vol. 43, no. January, pp. 14–31, 2020.

IDF, “International Diabetes Federation - Type 2 diabetes,†International Diabetes Federation, 2019. [Online]. Available: https://www.idf.org/aboutdiabetes/type-2-diabetes.html. [Accessed: 03-Apr-2020].

PERKENI, “Pedoman Pengelolaan dan Pencegahan Diabates Melitus Tipe 2 Dewasa,†in Pedoman Pengelolaan dan Pencegahan Diabates Melitus Tipe 2 Dewasa di Indonesia, Pertama De., D. Lindarto, Ed. Jakarta: PB PERKENI, 2019, pp. 1–132.

A. J. Garber et al., “Consensus statement by the American Association of clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary,†Endocr. Pract., vol. 26, no. 1, pp. 107–139, 2020.

N. D. DiPiro et al., “Lower extremity strength is correlated with walking function after incomplete SCI,†Top. Spinal Cord Inj. Rehabil., vol. 21, no. 2, pp. 133–139, 2015.

Y. Handelsman et al., “American Association of Clinical Endocrinologists and American College of Endocrinology - Clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015,†Endocrine Practice, vol. 21, no. April. pp. 1–87, 2015.

Diabetes UK, “Our story Annual report and accounts 2018 Contents,†UK, 2018.

Anonim, “Royal Pharmaceutical Society of Great Britain,†Br. Med. Assoc., vol. 52, no. 116–117, pp. 1–12, 2006.

J. Thrasher, “Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies,†Am. J. Cardiol., vol. 120, no. 1, pp. S4–S16, 2017.

D. Bina et al., Pharmaceutical care untuk penyakit diabetes mellitus, Second. Jakarta: Bina Kefarmasian dan Alat Kesehatan, 2005.

R. C. Chen, Y. H. Huang, C. T. Bau, and S. M. Chen, “A recommendation system based on domain ontology and SWRL for antidiabetic drugs selection,†Expert Syst. Appl., vol. 39, no. 4, pp. 3995–4006, 2012.

S. M. Chen, Y. H. Huang, and R. C. Chen, “A recommendation system for antidiabetic drugs selection based on fuzzy reasoning and ontology techniques,†Int. J. Pattern Recognit. Artif. Intell., vol. 27, no. 4, 2013.

R. C. Chen, H. Q. Jiang, C. Y. Huang, and C. T. Bau, “Clinical Decision Support System for Diabetes Based on Ontology Reasoning and TOPSIS Analysis,†J. Healthc. Eng., vol. 2017, pp. 9–12, 2017.

PERKENI, “Pengelolaan dan Pengobatan Diabetes Melitus Tipe 2 Dewasa,†in Pedoman Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia, Pertama., vol. 1, D. D. S. A. Soelistijo, Ed. Jakarta: PB PERKENI, 2019, p. 132.

H. Soetanto, S. Hartati, R. Wardoyo, and S. Wibowo, “Hypertension drug suitability evaluation based on patient condition with improved profile matching,†Indones. J. Electr. Eng. Comput. Sci., 2018.

Kemenkes RI, “Modul Penggunaan Obat Rasional,†kemenkes RI, pp. 3–8, 2011.

American Diabetes Association, “Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020,†Diabetes care, vol. 43, no. January. pp. S98–S110, 2020.

Diabetes Federation International, IDF Diabetes Atlas Ninth edition 2019. 2019.

F. R. Guilherme, C. A. Molena-Fernandes, V. R. Guilherme, M. T. M. Fávero, E. J. B. dos Reis, and W. Rinaldi, “Body mass index, waist circumference, and arterial hypertension in students,†Rev. Bras. Enferm., vol. 68, no. 2, pp. 190–194, 2015.

P. Pendidikan, D. Spesialis, P. Klinik, R. Sakit, and H. Sadikin, “Pemeriksaan Fungsi Ginjal,†CKD-237, vol. 43, no. 2, pp. 148–154, 2016.

S. S. Schwartz, S. Epstein, B. E. Corkey, S. F. A. Grant, J. R. Gavin, and R. B. Aguilar, “The time is right for a new classification system for diabetes: Rationale and implications of the β-cell-centric classification schema,†Diabetes Care, vol. 39, no. 2, pp. 179–186, 2016.

C. Prontera et al., “Proficiency testing project for brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP (NT-proBNP) immunoassays: the CardioOrmocheck study,†vol. 47, no. January 2005, pp. 762–768, 2009.

D. Care and S. S. Suppl, “9. Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetesd2019,†Diabetes Care, vol. 42, no. January, pp. S90–S102, 2019.

J. Dolenšek, M. S. Rupnik, and A. Stožer, “Structural similarities and differences between the human and the mouse pancreas,†Islets, vol. 7, no. 1, 2015.

H. Marcovitch, Black’s Medical Dictionary, 41st ed. London: A & C Black, 2005.

H. Ari Suhartanto, Kusrini, “Decision Support System Untuk Penilaian Kinerja Guru Dengan Metode Profile Matching,†J. Komput. Terap., vol. 2, no. 2, pp. 149–158, 2016.

H. P. Sri Kusuma Dewi, Aplikasi Logika Fuzzy untuk Pendukung Keputusan, Kedua., vol. Kedua. Yogyakarta: Graha Ilmu, 2010.

P. Made and S. D. Pathni, “Terapi Diabetes dengan SGLT-2 Inhibitor,†vol. 46, no. 6, pp. 452–456, 2019.

I. Saritas, I. A. Ozkan, and N. Allahverdi, “Determination of the drug dose by fuzzy expert system in treatment of chronic intestine inflammation Determination of the drug dose by fuzzy expert system,†J Intell Manuf Springer, no. April, p. 9, 2009.

M. Eghbali-Zarch, R. Tavakkoli-Moghaddam, F. Esfahanian, M. M. Sepehri, and A. Azaron, “Pharmacological therapy selection of type 2 diabetes based on the SWARA and modified MULTIMOORA methods under a fuzzy environment,†Artif. Intell. Med., vol. 87, pp. 20–33, 2018.

M. Al Switi, B. Alshraideh, A. Alshraideh, A. Massad, and M. Alshraideh, “Treatment of diabetes type II using genetic algorithm,†Int. J. online Biomed. Eng., vol. 15, no. 11, pp. 53–68, 2019.

L. Qin and V. Atluri, “Evaluating the validity of data instances against ontology evolution over the Semantic Web,†Inf. Softw. Technol., vol. 51, no. 1, pp. 83–97, 2009.

DOI: http://dx.doi.org/10.18517/ijaseit.11.3.12277


  • There are currently no refbacks.

Published by INSIGHT - Indonesian Society for Knowledge and Human Development